読み込み中
Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. The firm primarily targets serious conditions such as non-alcoholic steatohepatitis (NASH), various forms of mucopolysaccharidoses (MPS), and other significant diseases. The company's most advanced experimental drug is Lanifibranor, which has successfully completed Phase IIb clinical trials for the treatment of NASH. Inventiva is also progressing with Odiparcil, an asset that has finished its Phase IIa clinical studies for addressing the MPS VI subtype disease. Beyond these lead candidates, Inventiva maintains a robust pipeline of earlier-stage research and development programs, notably in oncology and other therapeutic areas. The company has also established important strategic alliances, including a partnership with AbbVie focused on treatments for autoimmune diseases, and a collaboration with Boehringer Ingelheim International GmbH aimed at discovering novel therapies for idiopathic pulmonary fibrosis. Inventiva S.A. was established in 2011 and is headquartered in Daix, France.
前日終値
€3.16
−€0.16 · -4.82%
日中の時刻はETです。市場データは遅延する場合があります。
Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. The firm primarily targets serious conditions such as non-alcoholic steatohepatitis (NASH), various forms of mucopolysaccharidoses (MPS), and other significant diseases. The company's most advanced experimental drug is Lanifibranor, which has successfully completed Phase IIb clinical trials for the treatment of NASH. Inventiva is also progressing with Odiparcil, an asset that has finished its Phase IIa clinical studies for addressing the MPS VI subtype disease. Beyond these lead candidates, Inventiva maintains a robust pipeline of earlier-stage research and development programs, notably in oncology and other therapeutic areas. The company has also established important strategic alliances, including a partnership with AbbVie focused on treatments for autoimmune diseases, and a collaboration with Boehringer Ingelheim International GmbH aimed at discovering novel therapies for idiopathic pulmonary fibrosis. Inventiva S.A. was established in 2011 and is headquartered in Daix, France.
日中レンジ
現在 €3.16
52週レンジ
現在 €3.16
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
11
著しい割高
センチメント
44
まちまち
リスク
66
高リスク
モメンタム
31
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. The firm primarily targets serious conditions such as non-alcoholic steatohepatitis (NASH), various forms of mucopolysaccharidoses (MPS), and other significant diseases. The company's most advanced experimental drug is Lanifibranor, which has successfully completed Phase IIb clinical trials for the treatment of NASH. Inventiva is also progressing with Odiparcil, an asset that has finished its Phase IIa clinical studies for addressing the MPS VI subtype disease. Beyond these lead candidates, Inventiva maintains a robust pipeline of earlier-stage research and development programs, notably in oncology and other therapeutic areas. The company has also established important strategic alliances, including a partnership with AbbVie focused on treatments for autoimmune diseases, and a collaboration with Boehringer Ingelheim International GmbH aimed at discovering novel therapies for idiopathic pulmonary fibrosis. Inventiva S.A. was established in 2011 and is headquartered in Daix, France.
日中レンジ
現在 €3.16
52週レンジ
現在 €3.16
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（EUR） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 448.3万 EUR | 919.8万 EUR | 1747.7万 EUR | 1217.9万 EUR | 419.4万 EUR |
| 売上原価 | 279.61万 EUR | 388.11万 EUR | −2.3万 EUR | 99.5万 EUR | 101.7万 EUR |
| 粗利益 | 151万 EUR | 919.8万 EUR | 1750万 EUR | 1705.7万 EUR | 419.4万 EUR |
| 研究開発 | 8360.76万 EUR | 9088万 EUR | 1.1億 EUR | 6046.9万 EUR | 4845.2万 EUR |
| 販売・一般管理 | 5389.2万 EUR | 1709.9万 EUR | 1560.7万 EUR | 1549.5万 EUR | 1152万 EUR |
| 営業費用 | 1.37億 EUR | 1.07億 EUR | 1.2億 EUR | 7416.7万 EUR | 5630.9万 EUR |
| 受取利息 | 282.88万 EUR | 114.3万 EUR | 94.5万 EUR | 39万 EUR | 5.7万 EUR |
| 支払利息 | 3229.6万 EUR | 1217.8万 EUR | 517.8万 EUR | 70.7万 EUR | 13.8万 EUR |
| 減価償却費と償却費 | 322.3万 EUR | 519.8万 EUR | 259.9万 EUR | 169.8万 EUR | 92.34万 EUR |
| 営業利益 | −1.31億 EUR | −9755.8万 EUR | −1.03億 EUR | −5711万 EUR | −5211.4万 EUR |
| 純利益 | −3.4億 EUR | −1.84億 EUR | −1.1億 EUR | −5427.4万 EUR | −4963.6万 EUR |
会社概要が更新されました 2026年10月12日.
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
€14.00
上昇余地（343.04%）この株式へのエクスポージャーを報告している上場投資信託です。
Simplify Propel Opportunities ETFSURI99.06万1.30%7606.44万 USD2.82%$17.06-0.14%
State Street SPDR S&P International Small Cap ETFGWX39.25万0.04%9.08億 USD0.40%$45.56+0.93%
Harbor Health Care ETF (MEDI)MEDI11.29万0.28%4144.63万 USD0.80%$32.48+1.81%
ActivePassive International Equity ETFAPIE4.37万—11.41億 USD0.45%$38.56+0.65%
State Street SPDR Portfolio Europe ETFSPEU2.49万0.00%6.83億 USD0.07%$53.13+0.68%Simplify Propel Opportunities ETFSURIState Street SPDR S&P International Small Cap ETFGWXHarbor Health Care ETF (MEDI)MEDIActivePassive International Equity ETFAPIEState Street SPDR Portfolio Europe ETFSPEUAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
